Application using non-covalent bond between a cucurbituril derivative and a ligand

A kit comprising:

• a first component that is a compound of formula (1) below bound to a first material;
• and
• a second component that is a ligand bound to a second material,
• wherein each of the first and second materials is independently selected from the group consisting of a solid phase, a biomolecule, an antioxidant, a chemical therapeutic agent, an anti-histaminic agent, a cucurbituril dendrimer, a cyclodextrin derivative, a crown ether derivative, a calixarene derivative, a cyclophane derivative, a cyclic peptide derivative, a metallic ion, a chromophore, a fluorescent material, a phosphor, a radioactive material, and a catalyst;
• and
• the ligand can non-covalently bind to the compound of formula (1) below, has at least one amine group, and is selected from the group consisting of a C1-C20 alkyl group;
• a C2-C20 alkenyl group;
• a C2-C20 alkynyl group;
• a C1-C20 alkoxy group;
• a C1-C20 aminoalkyl group;
• a C4-C20 cycloalkyl group;
• a C4-C7 heteroarylcyclo group;
• a C6-C20 aryl group;
• a C5-C20 heteroaryl group;
• a C1-C20 alkylsilyl group;
• a C6-C20 aryl group;
• a C5-C20 heteroaryl group;
• adamantane having a substituted or non-substituted C1-C20 alkyl group, C6-C20 aryl group or C5-C20 heteroaryl group;
• ferrocene or metallocene having a substituted or non-substituted C1-C20 alkyl group, C6-C20 aryl group or C5-C20 heteroaryl group;
• carborane having a substituted or non-substituted C1-C20 alkyl group, C6-C20 aryl group or C5-C20 heteroaryl group;
• fullerene having a substituted or non-substituted C1-C20 alkyl group, C6-C20 aryl group or C5-C20 heteroaryl group;
• cyclam or crown ether having a substituted or non-substituted C1-C20 alkyl group, C6-C20 aryl group or C5-C20 heteroaryl group;
• an oxygen-protected amino acid having a substituted or non-substituted C1-C20 alkyl group, C6-C20 aryl group or C5-C20 heteroaryl group;
• peptide having a substituted or non-substituted C1-C20 alkyl group, C6-C20 aryl group or C5-C20 heteroaryl group;
• alkaloid having a substituted or non-substituted C1-C20 alkyl group, C6-C20 aryl group or C5-C20 heteroaryl group;
• cisplatin having a substituted or non-substituted C1-C20 alkyl group, C6-C20 aryl group or C5-C20 heteroaryl group;
• oligonucleotide having a substituted or non-substituted C1-C20 alkyl group, C6-C20 aryl group or C5-C20 heteroaryl group;
• rhodamine having a substituted or non-substituted C1-C20 alkyl group, C6-C20 aryl group or C5-C20 heteroaryl group;
• and a nanoparticle having a substituted or non-substituted C1-C20 alkyl group, C6-C20 aryl group or C5-C20 heteroaryl group,
• where n is an integer from 6 to 10;
• X is O, S or NH;
• each of A1 and A2 is independently H, OR, SR, or NHR, and A1 and A2 are not simultaneously H,
• where R is selected from the group consisting of H;
• a substituted or non-substituted C1-C30 alkyl group;
• a substituted or non-substituted C2-C30 alkenyl group;
• a substituted or non-substituted C2-C30 alkynyl group;
• a substituted or non-substituted C2-C30 carbonylalkyl group;
• a substituted or non-substituted C1-C30 thioalkyl group;
• a substituted or non-substituted C1-C30 alkylthiol group;
• a substituted or non-substituted C1-C30 hydroxyalkyl group;
• a substituted or non-substituted C1-C30 alkylsilyl group;
• a substituted or non-substituted C1-C30 aminoalkyl group;
• a substituted or non-substituted C1-C30 aminoalkylthioalkyl group;
• a substituted or non-substituted C5-C30 cycloalkyl group;
• a substituted or non-substituted C2-C30 heterocycloalkyl group;
• a substituted or non-substituted C6-C30 aryl group;
• a substituted or non-substituted C6-C30 arylalkyl group;
• a substituted or non-substituted C4-C30 heteroaryl group;
• and a substituted or non-substituted C4-C30 heteroarylalkyl group.